Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2812-2823

  O'Shaughnessy, Joyce ^a   Miles, David ^a   Vukelja, Svetislava ^a   Moiseyenko, Vladimir ^a   Ayoub, Jean Pierre ^a   Cervantes, Guadalupe ^a   Fumoleau, Pierre ^a   Jones, Stephen ^a   Lui, Wing Yiu ^a   Mauriac, Louis ^a   Twelves, Chris ^a   Van Hazel, Guy ^a   Verma, Shailendra ^a   Leonard, Robert ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; MYALGIA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0037096755     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.002     Document Type: Article

References (31)

1. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
2. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
3. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2
4. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
5. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
6. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
7. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma
8. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
9. Efficacy and safety profile of capecitabine (Xeloda) in combination with paclitaxel (P) in patients with locally advanced or metastatic breast cancer: Preliminary results of a phase II study
10. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
11. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
12. Preliminary results of a phase I/II study of weekly docetaxel (Taxotere) combined with intermittent capecitabine (Xeloda) for patients with anthracycline pre-treated metastatic breast cancer
13. A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC)
14. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated advanced breast cancer patients
15. TEX (Taxotere, epirubicin and Xeloda) regimen as first line chemotherapy in advanced breast cancer: A multicenter phase II study
16. Phase I study of vinorelbine (V) and capecitabine (C) in advanced breast cancer (ABC)
17. Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer
18. An EORTC-IDBBC phase I study of cyclophosphamide (C) and epirubicin (E) in combination with capecitabine (X) (CEX) as primary treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC)
19. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
20. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients
21. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
22. Introduction to sample size determination and power for clinical trials
23. Interpreting the significance of changes in health-related quality-of-life scores
24. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
25. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer
26. Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience
27. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
28. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An Intergroup trial